Daily Stock Analysis, ENDP, Endo International PLC, priceseries

Endo International PLC. Daily Stock Analysis
Stock Information
Open
2.35
Close
2.55
High
2.56
Low
2.27
Previous Close
2.26
Daily Price Gain
0.29
YTD High
12.49
YTD High Date
Feb 28, 2019
YTD Low
2.14
YTD Low Date
Aug 15, 2019
YTD Price Change
-5.16
YTD Gain
-66.93%
52 Week High
18.50
52 Week High Date
Oct 17, 2018
52 Week Low
2.14
52 Week Low Date
Aug 15, 2019
52 Week Price Change
-13.36
52 Week Gain
-83.97%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 7. 2017
7.44
Dec 22. 2017
7.90
11 Trading Days
6.21%
Link
LONG
Jun 5. 2018
6.51
Jul 16. 2018
10.42
28 Trading Days
60.07%
Link
LONG
Jul 17. 2018
10.83
Aug 24. 2018
15.58
28 Trading Days
43.90%
Link
LONG
Jan 4. 2019
8.32
Jan 22. 2019
9.40
11 Trading Days
13.02%
Link
Company Information
Stock Symbol
ENDP
Exchange
NasdaqGS
Company URL
http://www.endo.com
Company Phone
353-1-268-2000
CEO
Paul V. Campanelli
Headquarters
-
Business Address
MINERVA HOUSE, SIMMONSCOURT ROAD, BALLSBRIDGE, DUBLIN 4, IRELAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001593034
About

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded on October 31, 2013 and is headquartered Dublin, Ireland.

Description

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating Peyronie's and Dupuytren's contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.